Patents by Inventor Lieming Ding

Lieming Ding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EGFR INHIBITOR, COMPOSITION, AND METHOD FOR PREPARATION THEREOF
    Publication number: 20230133169
    Abstract: Provided are the compounds of Formula I, a method for using these compounds as an EGFR inhibitor, and a pharmaceutical composition comprising the compounds. The compound is used for treatment, prevention or amelioration of diseases or conditions such as cancer or infection.
    Type: Application
    Filed: October 13, 2020
    Publication date: May 4, 2023
    Applicant: BETTA PHARMACEUTICALS CO., LTD
    Inventors: Xiangyong LIU, Changyong QIU, Guolong DU, Qichao SHEN, Mengqiang LIU, Haitong SHENG, Lieming DING, Jiabing WANG
  • QUINOLYL PHOSPHINE OXIDE COMPOUND, AND COMPOSITION AND APPLICATION THEREOF
    Publication number: 20230131025
    Abstract: The present invention relates to a compound of formula (I), a method for using the compound as an EGFR inhibitor, and a pharmaceutical composition comprising the compound. The compound can be used for treatment, prevention or alleviation of diseases or disorders such as cancer or infection.
    Type: Application
    Filed: February 8, 2021
    Publication date: April 27, 2023
    Applicant: Betta Pharmaceuticals Co., Ltd.
    Inventors: Xiangyong LIU, Changyong QIU, Mengqiang LIU, Xiaodong SONG, Qichao SHEN, Guolong DU, Haitong SHENG, Lieming DING, Jiabing WANG
  • KRAS G12C INHIBITOR AND PHARMACEUTICAL USE THEREOF
    Publication number: 20230062486
    Abstract: Provided are compounds of formula (I), which have KRAS mutation tumor regulating activity. Also provided are a method for providing these compounds and a pharmaceutical composition comprising the same.
    Type: Application
    Filed: December 18, 2020
    Publication date: March 2, 2023
    Inventors: Hao Wu, Xiaoping Chen, Yuan Lu, Jun Yu, Xiujun Xie, Jiangqi He, Shuibiao Fu, Qi Shen, Letian Zhang, Xiaoguan Zhu, Hong Lan, Jiabing Wang, Lieming Ding
  • IMIDAZOLIDINONE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20230053342
    Abstract: An imidazolidinone compound represented by formula (I), or a stereoisomer thereof, a geometric isomer thereof, or a tautomer thereof, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound, a synthesis method therefor and use thereof.
    Type: Application
    Filed: November 4, 2020
    Publication date: February 23, 2023
    Applicant: BETTA PHARMACEUTICALS CO., LTD
    Inventors: Houxian ZU, Xizhen SONG, Kai CHEN, Xiangyong LIU, Jie CHEN, Yajing BIAN, Lieming DING, Jiabing WANG
  • COMPOUND FUNCTIONING AS BROMODOMAIN PROTEIN INHIBITOR, AND COMPOSITION
    Publication number: 20230022091
    Abstract: The invention relates to a bromodomain inhibitor. The invention also provides compositions and formulations comprising such compounds, and methods of using and preparing such compounds.
    Type: Application
    Filed: August 29, 2022
    Publication date: January 26, 2023
    Applicant: Betta Pharmaceuticals Co., Ltd.
    Inventors: Yan XU, Xiaofeng XU, Jiabing WANG, Lieming DING
  • EGFR INHIBITOR, COMPOSITION AND PREPARATION METHOD THEREFOR
    Publication number: 20220402948
    Abstract: The present invention relates to the compounds of Formula I, methods of using these compounds as EGFR inhibitors, and pharmaceutical compositions comprising compounds thereof. The compounds are used for treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: September 25, 2020
    Publication date: December 22, 2022
    Inventors: Xiangyong LIU, Changyong QIU, Haitong SHENG, Mengqiang LIU, Qichao SHEN, Guolong DU, Xiaodong SONG, Lieming DING, Jiabing WANG
  • ERK inhibitor and use thereof
    Patent number: 11466013
    Abstract: Disclosed are a compound (as shown in formula I) as an extracellular signal-regulated kinase (ERK) inhibitor, a pharmaceutical composition thereof, a preparation method therefor, and use thereof in treating ERK-mediated diseases. Said compound plays a role by regulating a plurality of processes such as cell proliferation, apoptosis, migration and angiogenesis.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: October 11, 2022
    Assignee: Betta Pharmaceuticals Co., Ltd
    Inventors: Hao Wu, Wei Gu, Xiaojing Tang, Wei Wang, Bo Zhan, Dongjie Feng, Yongxin Ke, Zhongyan Chen, Yifei Shen, Wenmao Wu, Xintao Zhao, Hong Lan, Jiabing Wang, Lieming Ding
  • Compound functioning as bromodomain protein inhibitor, and composition
    Patent number: 11466034
    Abstract: The invention relates to a bromodomain inhibitor. The invention also provides compositions and formulations comprising such compounds, and methods of using and preparing such compounds.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: October 11, 2022
    Assignee: Betta Pharmaceuticals Co., Ltd.
    Inventors: Yan Xu, Xiaofeng Xu, Jiabing Wang, Lieming Ding
  • EGFR Inhibitor, Composition, and Preparation Method Therefor
    Publication number: 20220259235
    Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as EGFR inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: July 23, 2020
    Publication date: August 18, 2022
    Inventors: Xiangyong Liu, Changyong Qiu, Qichao Shen, Mengqiang Liu, Haitong Sheng, Xiaodong Song, Guolong Du, Jiabing Wang, Lieming Ding
  • EGFR INHIBITORS, COMPOSITIONS AND METHODS THERE OF
    Publication number: 20220227796
    Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as EGFR inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: March 31, 2020
    Publication date: July 21, 2022
    Inventors: Xiangyong LIU, Changyong QIU, Qichao SHEN, Mengqiang LIU, Haitong SHENG, Guolong DU, Jiabing WANG, Lieming DING
  • FGFR inhibitor and application thereof
    Patent number: 11365196
    Abstract: An azatricyclic compound (as represented by Formula I) which acts as an inhibitor of fibroblast growth factor receptors (FGFR), as well as a pharmaceutical composition thereof, a preparation method, and a use therefor in the treatment of FGFR-mediated diseases are provided. The azatricyclic compound exerts an effect by means of participating in the regulation of a plurality of processes such as cell proliferation, apoptosis, migration, neovascularization, and the like.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: June 21, 2022
    Assignee: Betta Pharmaceuticals Co., Ltd.
    Inventors: Xiaofeng Xu, Jiabing Wang, Lieming Ding, Xiangyong Liu
  • IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF
    Publication number: 20220119411
    Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: July 12, 2019
    Publication date: April 21, 2022
    Inventors: Bang FU, Yao ZHANG, Yiqian WANG, Xiangyong LIU, Jiabing WANG, Lieming DING
  • IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF
    Publication number: 20220098183
    Abstract: Provided herein are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: January 20, 2020
    Publication date: March 31, 2022
    Inventors: Yiqian WANG, Yao ZHANG, Bang FU, Jiabing WANG, Lieming DING
  • EGFR Inhibitors, Compositions and Methods Thereof
    Publication number: 20220064196
    Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as EGFR inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: January 14, 2020
    Publication date: March 3, 2022
    Inventors: Xiangyong LIU, Jiabing WANG, Lieming DING
  • FGFR4 INHIBITOR AND USE THEREOF
    Publication number: 20220002307
    Abstract: Disclosed is a compound as a fibroblast growth factor receptor 4 (FGFR4) inhibitor (as shown in formula (I)), and a pharmaceutical composition thereof and a preparation method therefor, as well as the use of same in the treatment of FGFR4-mediated diseases. The above-mentioned compounds act by participating in a number of processes, such as regulating cell proliferation, apoptosis, migration, neovascularization.
    Type: Application
    Filed: September 26, 2019
    Publication date: January 6, 2022
    Inventors: Jinheng GAO, Zhongxin SUN, Yun ZHANG, Xiaofeng XU, Xiangyong LIU, Jiabing WANG, Lieming DING
  • TYROSINE KINASE INHIBITORS, COMPOSITIONS AND METHODS THERE OF
    Publication number: 20210395256
    Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as Trk inhibitors, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: December 6, 2019
    Publication date: December 23, 2021
    Inventors: Bang FU, Yinlong LI, Wei REN, Jie CHEN, Xiangyong LIU, Jiabing WANG, Lieming DING
  • SALT FORM AND CRYSTAL FORM OF NOVEL AZATRICYCLIC COMPOUND AND USE THEREOF
    Publication number: 20210340142
    Abstract: A maleate, mesylate, benzene sulfonate, hydrochloride, phosphate, L-tartrate, L-malate, citrate, and fumarate of a compound represented by structural formula I, various crystal forms of each salt form, and a preparation method and application thereof.
    Type: Application
    Filed: August 27, 2019
    Publication date: November 4, 2021
    Inventors: Xiaofeng XU, Jiabing WANG, Lieming DING
  • IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF
    Publication number: 20210300909
    Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: July 19, 2019
    Publication date: September 30, 2021
    Inventors: Yiqian WANG, Yao ZHANG, Bang FU, Jiabing WANG, Lieming DING
  • IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF
    Publication number: 20210269440
    Abstract: The present invention relates to compounds of Formula I, methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Application
    Filed: July 19, 2019
    Publication date: September 2, 2021
    Inventors: Yao ZHANG, Yiqian WANG, Bang FU, Jie CHEN, Jiabing WANG, Lieming DING
  • ERK INHIBITOR AND USE THEREOF
    Publication number: 20210261552
    Abstract: Disclosed are a compound (as shown in formula I) as an extracellular signal-regulated kinase (ERK) inhibitor, a pharmaceutical composition thereof, a preparation method therefor, and use thereof in treating ERK-mediated diseases. Said compound plays a role by regulating a plurality of processes such as cell proliferation, apoptosis, migration and angiogenesis.
    Type: Application
    Filed: June 6, 2019
    Publication date: August 26, 2021
    Applicant: Betta Pharmaceuticals Co., LTD
    Inventors: Hao WU, Wei GU, Xiaojing TANG, Wei WANG, Bo ZHAN, Dongjie FENG, Yongxin KE, Zhongyan CHEN, Yifei SHEN, Wenmao WU, Xintao ZHAO, Hong LAN, Jiabing WANG, Lieming DING